Vishnu Anand Cuddapah

Vishnu Anand Cuddapah

Auto-generated profile, based on publicly available information

Vishnu Anand Cuddapah

Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2014 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
VCVishnu Anand Cuddapah
Vishnu Anand Cuddapah
SRStefanie Robel
Stefanie Robel
SWStacey Watkins
Stacey Watkins
Harald SontheimerHarald Sontheimer
Harald Sontheimer

7 January 2014 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
VCVishnu Anand Cuddapah
Vishnu Anand Cuddapah
RPRajesh B Pillai
Rajesh B Pillai
KSKiran V Shekar
Kiran V Shekar
JLJane B Lane
Jane B Lane
KMKathleen J Motil
Kathleen J Motil
MOMichelle Olsen
Michelle Olsen
Background Rett syndrome (RTT), a neurodevelopmental disorder that primarily affects girls, is characterised by a period of apparently normal development until 6–18 months of age when motor and communication abilities regress. More than 95% of individuals with RTT have mutations in methyl-CpG-binding protein 2 (MECP2), whose protein product modulates gene transcription. Surprisingly, although the disorder is caused by mutations in a single gene, disease severity in affected individuals can be quite variable. To explore the source of this phenotypic variability, we propose that specific MECP2 mutations lead to different degrees of disease severity. Methods Using a database of 1052 participants assessed over 4940 unique visits, the largest cohort of both typical and atypical RTT patients studied to date, we examined the relationship between MECP2 mutation status and various phenotypic measures over time. Results In general agreement with previous studies, we found that particular mutations, such as p.Arg133Cys, p.Arg294X, p.Arg306Cys, 3° truncations and other point mutations, were relatively less severe in both typical and atypical RTT. In contrast, p.Arg106Trp, p.Arg168X, p.Arg255X, p.Arg270X, splice sites, deletions, insertions and deletions were significantly more severe. We also demonstrated that, for most mutation types, clinical severity increases with age. Furthermore, of the clinical features of RTT, ambulation, hand use and age at onset of stereotypies are strongly linked to overall disease severity. Conclusions We have confirmed that MECP2 mutation type is a strong predictor of disease severity. These data also indicate that clinical severity continues to become progressively worse regardless of initial severity. These findings will allow clinicians and families to anticipate and prepare better for the needs of individuals with RTT.

9 March 2016 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SNSinifunanya E. Nwaobi
Sinifunanya E. Nwaobi
VCVishnu A. Cuddapah
Vishnu A. Cuddapah
KPKelsey Patterson
Kelsey Patterson
ARAnita C. Randolph
Anita C. Randolph
MOMichelle Olsen
Michelle Olsen

1 July 2019 in Trends in Neurosciences
Verified
Journal Article
Closed access
VCVishnu Anand Cuddapah
Vishnu Anand Cuddapah
SZShirley L. Zhang
Shirley L. Zhang
ASAmita Sehgal
Amita Sehgal

26 July 2014 in Glia
Verified
Journal Article
Closed access
PDF file
SCSusan L. Campbell
Susan L. Campbell
SRStefanie Robel
Stefanie Robel
VCVishnu A. Cuddapah
Vishnu A. Cuddapah
SRStephanie Robert
Stephanie Robert
SBSusan C. Buckingham
Susan C. Buckingham
Harald SontheimerHarald Sontheimer
Harald Sontheimer

1 September 2011 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
VCVishnu Anand Cuddapah
Vishnu Anand Cuddapah
Harald SontheimerHarald Sontheimer
Harald Sontheimer
A hallmark of high-grade cancers is the ability of malignant cells to invade unaffected tissue and spread disease. This is particularly apparent in gliomas, the most common and lethal type of primary brain cancer affecting adults. Migrating cells encounter restricted spaces and appear able to adjust their shape to accommodate to narrow extracellular spaces. A growing body of work suggests that cell migration/invasion is facilitated by ion channels and transporters. The emerging concept is that K+ and Cl− function as osmotically active ions, which cross the plasma membrane in concert with obligated water thereby adjusting a cell's shape and volume. In glioma cells Na+-K+-Cl− cotransporters (NKCC1) actively accumulate K+ and Cl−, establishing a gradient for KCl efflux. Ca2+-activated K+ channels and voltage-gated Cl− channels are largely responsible for effluxing KCl promoting hydrodynamic volume changes. In other cancers, different K+ or even Na+ channels may function in concert with a variety of Cl− channels to support similar volume changes. Channels involved in migration are frequently regulated by Ca2+ signaling, most likely coupling extracellular stimuli to cell migration. Importantly, the inhibition of ion channels and transporters appears to be clinically relevant for the treatment of cancer. Recent preclinical data indicates that inhibition of NKCC1 with an FDA-approved drug decreases neoplastic migration. Additionally, ongoing clinical trials demonstrate that an inhibitor of chloride channels may be a therapy for the treatment of gliomas. Data reviewed here strongly indicate that ion channels are a promising target for the development of novel therapeutics to combat cancer.